Article Versions Notes

Gifre-Renom L, Ugarte-Berzal E, Martens E, Boon L, Cano-Garrido O, Martínez-Núñez E, Luque T, Roca-Pinilla R, Conchillo-Solé Ò, Ferrer-Miralles N, et al. Recombinant Protein-Based Nanoparticles: Elucidating Their Inflammatory Effects In Vivo and Their Potential as a New Therapeutic Format. Pharmaceutics. 2020; 12(5):450. https://doi.org/10.3390/pharmaceutics12050450

Gifre-Renom, Laia, Estefania Ugarte-Berzal, Erik Martens, Lise Boon, Olivia Cano-Garrido, Esther Martínez-Núñez, Teresa Luque, Ramon Roca-Pinilla, Òscar Conchillo-Solé, Neus Ferrer-Miralles, and et al. 2020. "Recombinant Protein-Based Nanoparticles: Elucidating Their Inflammatory Effects In Vivo and Their Potential as a New Therapeutic Format" Pharmaceutics 12, no. 5: 450. https://doi.org/10.3390/pharmaceutics12050450

Gifre-Renom, L., Ugarte-Berzal, E., Martens, E., Boon, L., Cano-Garrido, O., Martínez-Núñez, E., Luque, T., Roca-Pinilla, R., Conchillo-Solé, Ò., Ferrer-Miralles, N., Villaverde, A., Opdenakker, G., Garcia-Fruitós, E., & Arís, A. (2020). Recombinant Protein-Based Nanoparticles: Elucidating Their Inflammatory Effects In Vivo and Their Potential as a New Therapeutic Format. Pharmaceutics, 12(5), 450. https://doi.org/10.3390/pharmaceutics12050450